| |
| |
|
| Insider
Information: |
Sato Vicki L |
| Relationship: |
|
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
7 |
|
| Direct
Shares |
1,672,571 |
|
|
Indirect Shares
|
8,084 |
|
|
| Direct
Value |
$36,205,289 |
|
|
|
Indirect Value
|
$3,213,228 |
|
|
| Total
Shares |
1,680,655 |
|
|
| Total
Value |
$39,418,517 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Vertex Pharmaceuticals Inc |
VRTX |
President |
2005-05-11 |
77,233 |
2005-05-11 |
8,084 |
Premium* |
|
|
Perkinelmer Inc |
PKI |
Director |
2017-02-09 |
29,970 |
2004-04-27 |
0 |
Premium* |
|
|
Infinity Pharmaceuticals Inc |
INFI |
Director |
2006-09-12 |
11,051 |
2006-09-12 |
0 |
Premium* |
|
|
Borgwarner Inc |
BWA |
Director |
2020-04-29 |
19,823 |
2014-04-30 |
0 |
Premium* |
|
|
Denali Therapeutics Inc. |
DNLI |
Director |
2024-04-15 |
118,043 |
2017-12-12 |
0 |
Premium* |
|
|
Vir Biotechnology, Inc. |
VIR |
Director |
2023-06-30 |
1,315,351 |
|
0 |
Premium* |
|
|
Allogene Therapeutics, Inc. |
ALLO |
|
2023-06-13 |
101,100 |
2021-07-30 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
226 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 10
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ALLO |
Allogene Therapeutics, In... |
|
– • – |
2021-07-30 |
4 |
A |
$0.00 |
$0 |
D/D |
19,362 |
19,362 |
0 |
- |
|
| ALLO |
Allogene Therapeutics, In... |
|
– • – |
2022-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
22,089 |
41,451 |
0 |
- |
|
| ALLO |
Allogene Therapeutics, In... |
|
• • – |
2023-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
59,649 |
101,100 |
0 |
- |
|
| BWA |
Borgwarner Inc |
Director |
• • – |
2014-04-30 |
4 |
A |
$61.40 |
$114,993 |
D/D |
1,873 |
1,873 |
0 |
- |
|
| BWA |
Borgwarner Inc |
Director |
• • – |
2015-04-29 |
4 |
A |
$60.95 |
$115,003 |
D/D |
1,887 |
3,777 |
0 |
- |
|
| BWA |
Borgwarner Inc |
Director |
• • – |
2016-04-27 |
4 |
A |
$39.29 |
$123,001 |
D/D |
3,131 |
6,930 |
0 |
- |
|
| BWA |
Borgwarner Inc |
Director |
• • – |
2017-04-26 |
4 |
A |
$41.13 |
$123,005 |
D/D |
2,991 |
9,921 |
0 |
- |
|
| BWA |
Borgwarner Inc |
Director |
• • – |
2018-04-25 |
4 |
A |
$52.91 |
$130,000 |
D/D |
2,457 |
12,378 |
0 |
- |
|
| BWA |
Borgwarner Inc |
Director |
– • – |
2019-04-24 |
4 |
A |
$43.55 |
$129,997 |
D/D |
2,985 |
15,404 |
0 |
- |
|
| BWA |
Borgwarner Inc |
Director |
• • – |
2020-04-29 |
4 |
A |
$29.67 |
$130,014 |
D/D |
4,382 |
19,823 |
0 |
- |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2017-12-12 |
4 |
A |
$0.00 |
$0 |
D/D |
62,500 |
137,500 |
0 |
- |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2021-03-03 |
4 |
AS |
$60.36 |
$102,641 |
D/D |
(1,666) |
139,087 |
0 |
% |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2021-03-31 |
4 |
AS |
$54.38 |
$93,992 |
D/D |
(1,666) |
137,421 |
0 |
% |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2021-04-28 |
4 |
AS |
$60.71 |
$103,538 |
D/D |
(1,666) |
135,755 |
0 |
% |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2021-05-26 |
4 |
AS |
$64.90 |
$108,911 |
D/D |
(1,666) |
134,089 |
0 |
% |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2021-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,074 |
136,163 |
0 |
- |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2021-06-23 |
4 |
AS |
$70.20 |
$117,845 |
D/D |
(1,666) |
134,497 |
0 |
% |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2021-07-21 |
4 |
AS |
$64.25 |
$108,510 |
D/D |
(1,666) |
132,831 |
0 |
% |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2021-08-18 |
4 |
AS |
$51.26 |
$86,139 |
D/D |
(1,666) |
131,165 |
0 |
% |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2021-09-15 |
4 |
AS |
$52.28 |
$88,969 |
D/D |
(1,666) |
129,499 |
0 |
% |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2021-11-01 |
4 |
AS |
$50.05 |
$83,383 |
D/D |
(1,666) |
127,833 |
0 |
% |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2021-11-10 |
4 |
AS |
$52.49 |
$87,983 |
D/D |
(1,666) |
126,167 |
0 |
% |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2022-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
5,986 |
142,149 |
0 |
- |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2023-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
4,216 |
136,369 |
0 |
- |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2023-06-28 |
4 |
AS |
$29.55 |
$49,709 |
D/D |
(1,666) |
134,703 |
0 |
% |
|
226 Records found
|
|
Page 1 of 10 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
